Abstract
BackgroundDose reduction or stopping of TNF inhibitors (TNFi) appears to be feasible and safe in patients with rheumatoid arthritis (RA), but may lead to flaring. No factors, including DAS28-CRP, have...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
